cefuroxime axetil + clavulanic acid (General Pharmaceuticals)

Secoclav is an oral fixed-dose combination antibiotic containing cefuroxime axetil, a second-generation cephalosporin prodrug, and clavulanic acid, a beta-lactamase inhibitor. Cefuroxime axetil is hydrolyzed post-absorption to release active cefuroxime, which exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis. Clavulanic acid, a suicide inhibitor of beta-lactamases, binds irreversibly to these enzymes, preventing the degradation of cefuroxime and extending its spectrum of activity against beta-lactamase-producing, resistant bacterial strains. Developed by General Pharmaceuticals, Secoclav is approved for the treatment of various mild-to-moderate bacterial infections, including pharyngitis, tonsillitis, acute otitis media, acute bacterial maxillary sinusitis, respiratory tract infections, urinary tract infections, and skin and soft tissue infections.

Brand names

Secoclav

Other names

cefuroxime + clavulanic acidcefuroxime and clavulanic acidcefuroxime axetil + clavulanic acidcefuroxime axetil and clavulanic acidcefuroxime axetil/clavulanic acidcefuroxime/clavulanic acid